Table 5.
Assessment of Physician Drug Dosing using unadjusted Estimating Equations
| Drug (N Dosing level) |
Recommended Dosages (PO) |
GFR range (mL/min) |
N received this dose |
CKD-EPI | MDRD Study | Cockcroft-Gault | |||
|---|---|---|---|---|---|---|---|---|---|
| N in this GFR category |
N not dosed correctly |
N in this GFR category |
N not dosed correctly |
N in this GFR category |
N not dosed correctly |
||||
|
Nucleoside Reverse Transcriptase Inhibitor (NRTI)
| |||||||||
| Tenofovir (5) | 300 mg once daily | >49 | 124 | 118 | 6 | 116 | 8 | 115 | 9 |
| 300mg every 48h | 30 to 49 | 0 | 7 | 0 | 9 | 0 | 10 | 0 | |
| 300mg twice weekly | 10 to 29 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | |
| No recommendation | <10/ No HD | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 300mg every 7d | HD | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
|
| |||||||||
| Total (%) | 125 (100) | 7 (6) | 9 (7) | 10 (8) | |||||
|
| |||||||||
| Emtricitabine (4) |
200mg daily | >49 | 103 | 98 | 5 | 96 | 7 | 95 | 8 |
| 200mg every 48h | 30 to 49 | 0 | 5 | 0 | 7 | 0 | 8 | 0 | |
| 200mg every 72h | 15 to 29 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 200mg every 96h | <15 or HD | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
|
| |||||||||
| Total (%) | 103 (100) | 5 (5) | 7 (7) | 8 (8) | |||||
|
| |||||||||
| Combination Pills | |||||||||
|
| |||||||||
| Tenofovir/ emtricitabine (3) |
1 tablet once daily | >49 | 43 | 39 | 4 | 37 | 6 | 35 | 8 |
| 1 tablet every 48h | 30 to 49 | 0 | 4 | 0 | 6 | 0 | 8 | 0 | |
| Not recommended | <30 or HD | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
|
| |||||||||
| Total (%) | 43 (100) | 4 (9) | 6 (14) | 8 (19) | |||||
|
| |||||||||
| Tenofovir/ emtricitabine/ efavirenz (2) |
1 tablet once daily | >50 | 37 | 36 | 1 | 35 | 2 | 36 | 1 |
| Not recommended | <50 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | |
|
| |||||||||
| Total (%) | 37 (100) | 1 (3) | 2 (5) | 1 (3) | |||||
|
| |||||||||
| Abacavir/ lamivudine (2) |
1 tablet once daily | >50 | 24 | 21 | 3 | 21 | 3 | 22 | 2 |
| Not recommended | <50 | 0 | 3 | 0 | 3 | 0 | 2 | 0 | |
|
| |||||||||
| Total (%) | 24 (100) | 3 (13) | 3 (13) | 2 (8) | |||||
Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; MDRD Study, Modification of Diet in Renal Disease Study; GFR, glomerular filtration rate
Tenofovir (Viread®), Emtricitabine (Emtriva®), tenofovir/ emtricitabine (Truvada®), tenofovir/ emtricitabine/ efavirenz (Atripla™), abacavir/lamivudine (Epzicom™ )